|
|
||||||||
Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226
| |
ABSTRACT |
|---|
|
|
|---|
The unique role of nitric oxide (NO) in the regulation of renal medullary function is supported by the evidence summarized in this review. The impact of reduced production of NO within the renal medulla on the delivery of blood to the medulla and on the long-term regulation of sodium excretion and blood pressure is described. It is evident that medullary NO production serves as an important counterregulatory factor to buffer vasoconstrictor hormone-induced reduction of medullary blood flow and tissue oxygen levels. When NO synthase (NOS) activity is reduced within the renal medulla, either pharmacologically or genetically [Dahl salt-sensitive (S) rats], a super sensitivity to vasoconstrictors develops with ensuing hypertension. Reduced NO production may also result from reduced cellular uptake of L-arginine in the medullary tissue, resulting in hypertension. It is concluded that NO production in the renal medulla plays a very important role in sodium and water homeostasis and the long-term control of arterial pressure.
renal medulla; Dahl salt-sensitive rats; hypertension; L-arginine
| |
INTRODUCTION |
|---|
|
|
|---|
THE RENAL MEDULLARY CIRCULATION is now recognized to be of importance for reasons that extend far beyond providing the economy of countercurrent exchange to concentrate large volumes of filtrate to produce small volumes of concentrated urine. It is now recognized that medullary blood flow (MBF) can play an important role in determining long-term levels of arterial pressure and that 15-30% reductions of blood flow to the renal medulla in the face of imperceptibly small changes of total renal blood flow can lead to the development of hypertension (16, 21). Evidence is reviewed showing that nitric oxide (NO) plays a unique role in the acute and chronic regulation of renal MBF, sodium homeostasis, and arterial pressure. More specifically, the role of NO in the regulation of MBF, in linking tubular metabolic needs with delivery of nutrients and as a counterregulatory system to protect the medulla from the consequences of underperfusion, are the focus of this review. The influence of NO on the renal cortex and such issues that relate to pressure-natriuresis, autoregulation of total renal blood flow, tubuloglomerular feedback, and glomerular filtration rate (GFR) regulation are important subjects of renal function that either have been reviewed by others (2, 29, 43, 55, 96) or are beyond the scope of this relatively brief review.
| |
NO PRODUCTION AND THE OVERALL REGULATION OF RENAL FUNCTION |
|---|
|
|
|---|
NO within the kidney is now known to contribute importantly to low renal vascular resistance (75, 115) and to be able to stimulate natriuresis and diuresis independent of renal perfusion pressure as reviewed by others (2, 5, 43, 50, 75, 104, 137). The slope of the pressure-natriuresis relationship has been shown to be reduced with the inhibition of renal NO synthase (NOS) activity (23, 28, 98). As reviewed recently by Liang and Knox (50) and by Ortiz and Garvin (80), there is evidence that NO reduces sodium reabsorption in all tubular segments, including the proximal tubule (50, 80), thick ascending limb (78, 79), distal tubules, and cortical collecting ducts (80), although medullary nephron segments and collecting ducts remain to be studied in detail. Studies have also demonstrated that tubuloglomerular feedback control of afferent arteriolar resistance is influenced by macula densa NO production, thereby enhancing autoregulation of renal blood flow, GFR, and renin secretion (30, 37, 53, 75, 122, 128).
| |
INITIAL EVIDENCE THAT NO PARTICIPATES IN THE ACUTE REGULATION OF MEDULLARY FUNCTION |
|---|
|
|
|---|
Evidence that an endothelial-derived relaxing factor (EDRF) within the renal medulla could play a role in medullary oxygenation was first reported by Biondi et al. (6). Functional evidence that basal levels of NO contribute to MBF resulted from a series of studies in our laboratory that examined the effects of a variety of vasoactive compounds on MBF. These compounds were assessed by direct delivery into the medullary interstitial space of rats by use of a small implanted catheter (51, 52), whereas MBF responses were determined using external and implanted optical fibers and laser-Doppler flowmetry techniques (52). Substances infused into the medullary interstitium became trapped and concentrated by the countercurrent vasa recta circulation, enabling responses to be determined independent of the cortex.
It was found that the most dramatic reduction of MBF was obtained with medullary infusion of the nonspecific NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) (62), a compound that reduced flow to this region by nearly 40% (61). No changes of cortical flow were observed. Similarly, infusions of bradykinin (57) and acetylcholine (62), NO-dependent vasodilators, also produced substantial increases of MBF. Several important conclusions were drawn from these in vivo studies in anesthetized rats. First, MBF could be modulated independently of cortical blood flow (CBF). Second, the medullary vasculature could respond to many of the same vasoactive compounds as arterioles in other regions of the body. Third, NO exerted a tonic influence on the renal medullary vasculature.
| |
LOCALIZATION OF NO PRODUCTION WITHIN VASCULAR AND TUBULAR STRUCTURES OF THE KIDNEY |
|---|
|
|
|---|
The extent to which the antinatriuresis associated with medullary NOS inhibition was a direct consequence of reduction of MBF (16, 102) or was related to changes of intrarenal paracrine/autocrine systems (95, 100) or was a direct consequence of tubular epithelial transport actions of NO (80, 136) awaited a better understanding of the intrarenal sites of NO production. Initial efforts to determine regional NO biosynthesis by determining tissue nitrite/nitrate and cGMP levels in slices of dissected renal zones, isolated glomeruli, and various cell cultures systems. These studies indicated that tissues of both the renal cortex and medulla were indeed capable of generating NO in abundant amounts (6, 10, 13, 25, 36, 69, 93, 108).
Recently, techniques have enabled discrete measurements of segmental
tubular and microvascular measurements of NOS enzyme activity,
expression of the mRNA and protein levels, and interstitial fluid NO
concentrations ([NO]). NOS activity assays incubated tissue protein
with L-[3H]arginine and appropriate cofactors
and the conversion of L-arginine (L-Arg) to
L-citrulline (Cit) was quantified by reverse-phase HPLC
and radiochemical detection (63, 68). Evidence was
obtained showing that the renal medulla is the major source of NO
production in the rat kidney. Regional comparisons of NOS activity and
[NO] are summarized in Fig. 1. NOS
activity was found to be 26 times higher in the inner medulla and 4 times higher in the outer medulla than in the renal cortex of
Sprague-Dawley rats (130). In vivo microdialysis
techniques using oxyhemoglobin in the dialysate to trap tissue NO found
that concentrations of interstitial fluid NO averaged nearly 105 ± 18 nmol/l in the renal medulla compared with 62 ± 16 nmol/l in
the cortex (138). These observations conform with data
showing that NOS I and NOS II mRNA levels were more than five times
greater in the outer medulla of Brown Norway (BN) rats compared with
cortex (132). Moreover, the protein expression levels of
all three isoforms determined by Western blot analysis were observed to
be three to five times higher in this region in BN rats (Cowley,
unpublished observations), as also reported for NOS III in kidneys of
Sprague-Dawley rats (77).
|
The capacity to produce NO is best represented by NOS activity, and
studies have been carried to determine activity levels in
microdissected glomeruli, tubular, and microvascular segments of the
cortex and medulla of Sprague-Dawley rat kidneys (130). Inner medullary collecting ducts (IMCD) were found to contain the
greatest levels of NOS activity (11.5 fmol
Cit · mm
1 · h
1),
greatly exceeding the activity found in the glomeruli (1.9 fmol
Cit · glomerulus
1 · h
1).
All other tubular elements exhibited significantly less NOS activity,
including proximal convoluted tubule, pars convoluta, pars recta,
cortical thick ascending limb, cortical collecting duct, outer
medullary collecting duct, outer medullary thick ascending limb, and
inner medullary thin limb. The medullary vasa recta bundles of the
outer medulla contained relatively high levels of total NOS enzymatic
activity (3.2 fmol
Cit · mm
1 · h
1),
exceeded only by that in the IMCDs. Only about one-third as much was
found in the afferent arterioles and considerably less in the arcuate
and interlobular arteries (63). Similar results were found
when relative enzyme activity levels were expressed based on segment
length or as total protein.
NOS I and NOS III mRNA was found to be expressed in both the glomeruli and in the vasa recta, whereas the IMCD contained mRNA for all three of the NOS isoforms (130). As initially observed by Terada et al. (121) and later confirmed by Ugie et al. (125) and ourselves (63), there appears to be little or no NOS mRNA for any of the known isoforms expressed in rat early proximal tubule, although NOS II mRNA was reported to be expressed in the S3 segment of the proximal tubule, based on in situ hybridization studies (121). Taken together, the data indicate that the NOS activity in IMCDs contributes importantly to the higher levels of interstitial [NO] observed in the medulla compared with the cortex.
| |
EVIDENCE FOR PARACRINE AND AUTOCRINE NO FUNCTION IN THE RENAL MEDULLA ("TUBULOVASCULAR CROSS-TALK") |
|---|
|
|
|---|
The use of fluorescent dyes for detection of NO and
Ca2+ ions has begun to provide insights regarding the
ability of medullary tubular epithelial cells to act as a paracrine NO
source for the regulation of vasa recta function. The focus of these
studies has been on the larger diameter vasa recta vessels of the outer medulla for reasons related to the unique structure and function of the
medullary vasa recta circulation. Before the results of these studies
are reviewed, it is important to first appreciate the microvascular
anatomy of the renal medulla, as described in detail by others
(3, 4, 40, 44, 64, 81-83, 127). In brief, it is
recognized that blood flow to the medulla of mammalian kidneys is
supplied by postglomerular microvessels derived from juxtamedullary
glomeruli, the deep glomeruli of the inner cortex that receive their
blood supply from the interlobular branches of the arcuate arteries, as
described by Kaissling and Kriz (39). A photomicrograph of
one of these juxtamedullary glomeruli (Glm) is shown in Fig.
2A. As seen in this figure,
the efferent arterioles of these juxtamedullary glomeruli immediately
radiate into the vasa recta capillary bundles of the outer medulla
(OMDVR) that then coalesce into long descending vasa recta (DVR) loops
supplying the inner medulla and papilla. Although the blood flow to the medulla emanates from the renal cortex (CX) and changes of cortical flow can importantly influence blood flow to the medullary region, there is evidence as presented in this review that flow to the medulla
can be independently modulated. Regional regulation of MBF is important
to supply nutrients and remove tubular reabsorbate. It is important to
preserve the interstitial gradients for NaCl and urea established by
the loops of Henle and collecting ducts for urine concentration.
|
Medullary DVR vessels are unique in that they have characteristics of
true capillaries with continuous endothelium but are also surrounded by
smooth muscle remnants known as pericytes, as shown in Fig.
2C. The DVR pericytes contain
-smooth muscle actin
(88), and the ability of the pericytes to constrict and reduce the diameter of DVR has been demonstrated by Pallone and colleagues (86) using isolated perfused vasa recta vessels
from the outer medulla. For example, these vessels have been shown to
respond to vasoconstrictors such as ANG II, as shown in Fig. 3A (85), AVP
(124), and endothelin (112), as well as
vasodilators such as bradykinin (83), prostaglandin
E2 (112), and adenosine (111).
The ability of the DVR to behave like small arterioles accounts for the
ability of the medullary flow to be controlled independently from the
cortical circulation when vasoactive substances are endogenously
released or infused. This also accounts for the in vivo medullary flow
responses observed when vasoactive agents are delivered into the renal
medullary interstitium, such as AVP (72), norepinephrine
(NE) (135), and ANG II (138). ANG II-induced reduction of
MBF was also shown to be significantly enhanced by pretreatment with
the cyclooxygenase inhibitor meclofenamate (61).
|
On the basis of these anatomic structures and blood flow responses of the outer medulla, studies were carried out to determine whether NO produced by the tubular epithelium of the medullary thick ascending limbs of Henle (mTAL) might act both as an autocrine factor within tubular epithelia and as a paracrine factor on surrounding structures. Although nephron segments are largely excluded from the central core of the vasa recta bundles, at the periphery of the bundle these vessels give rise to the dense capillary plexuses that perfuse the outer medulla. As shown in Fig. 2, A and B, these peripheral vasa recta are surrounded by medullary mTAL, and it was logical to examine whether these tubules could communicate information to the DVR via the release of NO.
The movement of NO in vivo has received far less attention than the biochemical reactions that control its rate of synthesis and degradation. The importance of the volatility, solubility, and diffusability of NO in determining its biological effects, however, has been studied in some detail and reviewed by Lancaster (46). The results have shown that under all physiological conditions (except when there is a gas-liquid interface as in the lung), NO exists completely as a dissolved nonelectrolyte. NO is slightly more soluble in aqueous solution than O2, and in virtually all its biological actions NO is not a gas unless concentrations approach 1-2 mmol/l, a highly unlikely situation in vivo. The solubility of NO, although similar to O2, is nearly nine times greater in organic solvents, so that NO concentrates in hydrophobic phases in tissues such as membranes, lipid inclusions, and lipoprotein complexes. The lipid bilayer of membranes therefore poses no barrier to the movement of NO in tissue. On the basis of mathematical modeling of the random diffusion of NO within tissues, it has been estimated that NO would be able to act at large distances from a single cellular source and thus affect an enormous number of other cells surrounding this single source (47). It has been estimated that NO could diffuse in tissues from 0.2 to 0.25 mm in 5-10 s (46), well within the range generally considered to be the tissue half-life of NO.
Microdialysis of renal interstitial fluid using oxyhemoglobin trapping has demonstrated relatively high levels of NO as well as nitrite concentrations in medullary interstitial fluid as shown in Fig. 1 (135, 136, 138). These NO levels were increased by intravenous infusion of L-Arg and decreased by L-NAME (136). Tubular and vascular segments of both the cortex and medulla therefore appear to be constantly exposed to NO that could serve a paracrine function.
Availability of novel fluorescent probes has enabled direct observation, at high temporal and spatial resolution, of the responses of intracellular NO and Ca2+ within renal tubular and epithelium vasa recta imaged from thin renal medullary tissue strips. Intracellular Ca2+ concentration ([Ca2+]i) has been quantified using fura 2-AM and changes of NO imaged using the NO-sensitive dye 4,5-diaminofluorescein deacetate (DAF-2DA). These techniques were initially used to study mechanisms of AVP-stimulated NO production in the IMCD epithelial cells. It was shown that AVP produced a rapid increase of [Ca2+]i followed by a significant increase of intracellular NO within these cells (67). The NO response was abolished both by an NO scavenger, carboxy 2-(4-carboxyphenyl)-4,4,5,5,tetramethylimidazoline-1-oxyl-3-oxide, and by preincubation with the Ca2+-ATPase inhibitor thapsigargin. These results clearly demonstrated that NO acts as a signaling molecule in the IMCD.
As illustrated in Fig. 3, studies have also shown that NO produced within the mTAL can serve both a paracrine and autocrine function to control vascular tone of the surrounding vasa recta. The paracrine function was demonstrated when techniques were developed to distinguish the fluorescent signals of the contractile pericytes from the stronger signals of the underlying vasa recta endothelial cells. To do this, the fluorescent signals of the underlying endothelial cells were abolished by perfusing the kidneys with 0.2-µm latex microspheres before the removal of the microtissue strip from the outer medulla for study under the fluorescent microscope. This enabled a 10-fold increase in fluorescent signal gain of the detection unit for the acquisition of the less intense signals of the vasa recta pericytes without overexposure of fluorescent signals from the endothelial cells. The NO response to ANG II of an outer medullary vasa recta pericyte surrounded by mTAL in the microtissue strip loaded with NO-sensitive dye DAF-2DA was then measured (Fig. 3C).
These techniques were used to determine if the constrictor actions of
ANG II on the vasa recta pericytes were buffered by NO produced by
either tubular epithelial cells surrounding the vasa recta and/or by NO
produced by endothelial cells within the vasa recta themselves
(21). Using thin microtissue strips, ANG II (1 µmol/l)
produced an increase of intracellular [NO] ([NO]i) in
the vasa recta pericytes only when the vessels were adjacent to the
mTAL. Pericytes of completely isolated vasa recta without surrounding
mTAL showed a rapid peak increase in [Ca2+]i
(21), consistent with observations of Reinhardt et al.
(97). Importantly, however, DVR pericytes did not show any
increase of NO production either in response to ANG II or with
administration of a Ca2+ ionophore, indicating a lack of
Ca2+-sensitive NO production in vasa recta pericytes. Using
isolated vasa recta with intact endothelium, ANG II was found to reduce Ca2+ within the endothelial cells as was also observed by
Pallone and colleagues (85, 86) and failed to increase NO,
although the Ca2+ ionophore was able to increase NO in
these endothelial cells. Tubular epithelial cells responded quite
differently in that increases of NO were observed in single isolated
mTAL in response to both ANG II and Ca2+ ionophore.
Although it is evident that the concentrations of ANG II used in these
studies far exceeded levels in the systemic circulation, it appears
that intrarenal levels may be as high as 10
9 to
10
10 mol/l (73, 107) so the medullary
structures may be exposed to nanomolar levels of ANG II
(75). Pallone et al. (85) observed isolated
DVR diameter reductions at concentrations of 10 nmol/l (see Fig.
3A).
The autocrine function of NO produced in rat thick ascending limb (TAL)
segments was established by Oritz and Garvin (78), who
demonstrated in perfused isolated tubules that endogenously produced NO
inhibited HCO3
transport. Although it is not
stated in this study whether TAL segments were obtained from the cortex
or medulla, it is likely that these events take place in both segments.
On the basis of these studies, autocrine/paracrine concepts emerged as
summarized in Fig. 4. ANG II increases
[NO]i in pericytes only when the vasa recta vessels are
surrounded by renal tubular segments, mostly mTAL in this case. Neither
the endothelium nor pericytes can directly increase NO production in
response to ANG II. ANG II increases intracellular calcium
concentration in the pericytes of the DVR, apparently as part of its
constrictor action on these vessels. This response is buffered by NO
diffusing from tubular elements surrounding vasa recta within the outer
medulla, a paracrine function that we have called tubulovascular
cross-talk. The close proximity of mTAL to the vasa recta bundles in
the outer medulla (~50-150 µm) suggests that these tubular
elements would be of greater importance in this paracrine cross-talk
than the outer medullary collecting ducts, which are of a greater
distance to the vessels (~150-250 µm) (39, 44,
49). The extent to which hemoglobin within the vasa recta
capillary circulation would modify the in vivo NO diffusion profile is
unclear. However, NO derived from mTAL is not exposed to hemoglobin
before reaching the pericytes of the vasa recta. Because there is
considerable interstitial space and fluid surrounding the individual
vasa recta to provide NO to the pericytes (~10- to 30-µm distances
separating the vasa recta; personal observation), intravascular
hemoglobin would not be expected to play a major role in buffering the
medullary interstitial NO gradients. The diameter of the entire vasa
recta bundle does not exceed the estimated diffusion distance of NO within biological fluids (0.2-0.25 mm) as indicated above
(46, 47). Finally, although the deep vasa recta of the
inner medulla remain to be studied, it is likely that these vessels may
be controlled in a similar fashion by the high levels of NO produced by
the epithelial cells of the IMCD, because pericytes have been shown to
exist surrounding these vasa recta, although less densely distributed (88).
|
| |
IMPORTANCE OF MEDULLARY NO PRODUCTION IN THE LONG-TERM CONTROL OF MBF AND ARTERIAL PRESSURE |
|---|
|
|
|---|
The first evidence that basal NO production played an important
role in determining arterial blood pressure arose from observations that chronic oral or intravenous administration of NOS inhibitors such
as L-NAME or
NG-monomethyl-L-arginine
(L-NMMA) produced hypertension (28, 32, 55,
123). It was unclear, however, whether the observed hypertension was primarily a result of generalized systemic vasoconstriction, an
effect of NO reduction in brain, or a primary consequence of reduced
renal excretory function. Studies were carried out to determine whether
medullary NO production per se played an important role in the
long-term regulation of renal MBF, sodium excretion, and arterial
pressure. L-NAME was infused chronically into the renal
medullary interstitium of Sprague-Dawley rats for 5 days. As shown in
Fig. 5, this renal interstitial (ri)
infusion of L-NAME resulted in a sustained reduction of
renal MBF (~30%) with no measurable changes of cortical flow as
determined daily in unanesthetized rats with chronically implanted
optical fibers. This reduction of MBF was associated with an immediate
reduction of sodium excretion, retention of sodium, and the development
of hypertension (59). This demonstrated that reduction of
NO production in the medulla alone could reduce MBF and produce
hypertension.
|
Consistent with these observations, it was also found that L-NAME administered in small doses by chronic intravenous infusion reduced MBF alone, independently of any changes in CBF, and this again led to sodium retention and hypertension (71). It had been assumed that hypertension resulting from systemically administered L-NAME was probably related to a reduction of total renal blood flow (75) and an overall increase in systemic vascular resistance related to vascular and central nervous system NOS inhibition. Together these studies with both systemic (intravenous) and renal medullary (ri) delivery of L-NAME demonstrated that the production of NO specifically within the medulla was of primary importance in the long-term regulation of MBF and sodium homeostasis and that reduction of NOS activity in the renal medulla alone could produce chronic hypertension.
| |
INFLUENCE OF MEDULLARY NO PRODUCTION ON BLOOD PRESSURE SALT SENSITIVITY |
|---|
|
|
|---|
Consistent with the influence of NO on tubular sodium reabsorption summarized above, it was found that systemic administration of nonspecific NOS inhibitors resulted in a sodium-dependent form of hypertension (28, 55, 70, 123). The extent to which reduction of medullary NO independent of the renal cortex could produce blood pressure salt sensitivity was determined by a series of studies In our laboratory. The effects of inhibiting two of the specific NOS isoforms, NOS I and NOS II, were examined. A salt-dependent form of hypertension occurred in Sprague-Dawley rats when an antisense oligonucleotide complementary to the code of the initiating region of the mRNA for NOS I synthesis was infused chronically into the medullary interstitial space (56). Similar responses were observed using a mechanistically different inhibitor of NOS I, 7-nitroindazole (7-NI) (56). The antisense probe reduced NOS I synthase activity by 53% and the 7-NI by 37%. In both cases, mean arterial pressure rose over 3 to 5 days to ~15 mmHg above resting control levels in rats receiving a high (4%)-salt diet, with no changes in pressure being observed in rats receiving the low-salt diet.
In another study, the effects of chronically inhibiting the inducible NOS II isoforms were examined (60). Chronic intravenous infusions of aminoguanidine in Sprague-Dawley rats that resulted in a 49% reduction of Ca2+-independent NOS (inducible NOS) in the renal medulla, produced a salt-dependent form of hypertension with mean arterial pressure rising nearly 15 mmHg when these rats were fed a high-salt (4%) diet. The results also suggested that these events occurred independently of renal vascular changes, because intravenous infusion of this inhibitor at the same dose in anesthetized rats resulted in no significant changes in mean arterial pressure, CBF, or MBF, whereas urine flow and sodium excretion were significantly decreased (60).
Thus it appears that reduction of NO production within the renal medulla alone can lead to a salt-sensitive form of hypertension. Tan et al. (120) observed hypertensive responses in the absence of any measurable changes in renal plasma flow or GFR with chronic intravenous administration of aminoguanidine in salt-resistant Dahl R rats exposed to a high-salt diet, consistent with predominant tubular effects. Recent work by Kakoki et al. (42) and Mattson et al. (60) using a variety of NOS isoform-specific inhibitors indicated that NO derived from NOS I and/or NOS II has minimal effect on blood flow in the renal medulla (42, 60). The results also suggest that the enhanced salt sensitivity with NOS inhibition may be largely a consequence of a reduction of NOS I and NOS II activity within the deep nephrons of the renal medulla. The role of NOS II, however, remains controversial given the lack of complete specificity of these inhibitors. The antinatriuretic effects of aminoguanidine have not been consistently observed by others (43), and firm conclusions regarding the specific roles of NOS II in the regulation of medullary function await final resolution.
The lack of availability of NOS III-specific inhibitors has precluded pharmacological approaches to examine this isoform. One would expect, however, that specific reductions of endothelial NOS would be accompanied by a lowering of MBF and chronic hypertension as seen with L-NAME administration. Huang et al. (33) observed hypertension in NOS III-knockout mice, demonstrating the importance of NOS III in long-term blood pressure regulation, but this study did not address the role of NOS III in the renal medulla. Inasmuch as NOS III is found in both endothelium of the vasa recta and the epithelial cells of mTAL and IMCD (see below), the NO produced by this NOS isoform could influence both tubular sodium reabsorption and MBF. Thus it will not be so easy to separate the relative contributions of NO from these specific regions upon the long-term control of arterial pressure.
The role of medullary NO in response to changes of sodium intake and the extent to which such changes participate in the regulation of MBF remain unclear. Studies in chronically instrumented Sprague-Dawley rats in our laboratory found no changes in MBF as daily sodium intake was increased from 0.4 to 4.0% (27). However, rats fed a high-sodium diet (4.0%) exhibited an increase in NOS-immunoreactive protein for all isoforms in the medullary tissue (58). Ni and Vaziri (76) observed a decrease in medullary protein expression of NOS I and II after 3 wk of an 8% sodium diet. Others found no change in medullary mRNA expression of any of the NOS isoforms (98, 113).
| |
ACUTE COUNTERREGULATORY ACTION OF RENAL MEDULLARY NO ON CIRCULATING VASOCONSTRICTORS |
|---|
|
|
|---|
The vascular counterregulatory functions of NO were first suspected, but the data supporting this role for NO were not initially forthcoming. Reduction of tissue NO production with NOS inhibition was found by some investigators to enhance ANG II-induced reduction of renal blood flow (1) and to potentiate the vasoconstrictor effects of ANG II in isolated perfused kidneys (105). Similar findings were obtained using the in vitro perfused juxtamedullary preparation (35) and in isolated perfused afferent arterioles (37). Others found no evidence of enhanced vasoconstriction to either ANG II or NE after NOS inhibition using a perfused split kidney juxtamedullary preparation when vessel diameter was restored to normal by sodium nitroprusside (35), or in studies using an in vitro hydronephrotic kidney preparation (87).
Considerable evidence has now emerged supporting the view that NO does serve an important counterregulatory role within the renal medullary circulation. In this regard, ANG II has been studied in some detail. There is abundant evidence that ANG II can stimulate NO production in many cell types, as shown by measurements of nitrate and cGMP production in neural, cardiac, vascular, and renal cells (8, 14, 34, 45, 106, 126, 133). ANG II also increases the renal excretion of nitrate and nitrite (20) and cGMP concentrations in renal cortical interstitial fluid as determined by microdialysis (110).
Results of these earlier studies were unable to provide conclusive evidence that NO served as an important counterregulatory system to vasoconstrictor agents in the renal medulla, because neither tissue [NO] nor MBF were measured directly. Both of these are needed to ascertain changes in local NO production. Blood flow measurement is important because [NO] alone need not reflect increased NO production, because medullary interstitial tissue and fluid [NO] can be hemodynamically influenced by the rate of blood flow through the countercurrent vasa recta circulation ("washout") and by shunt pathways in the outer medulla, as known to be the case with oxygen gradients.
Studies were therefore carried out to determine the in vivo effects of
ANG II on both MBF and interstitial fluid [NO] (via microdialysis
oxyhemoglobin trapping technique; Ref. 136). As shown in
Fig. 6A, intravenous infusion
of a subpressor dose of ANG II (5.0 ng · kg
1 · min
1)
produced no reduction of CBF, MBF, or medullary
PO2 levels. This level of infused ANG II,
however, did produce nearly a 150% rise of [NO] within the medullary
interstitial fluid (138). This ANG II-induced rise of
tissue fluid [NO] was abolished when medullary NOS activity was
blunted in these same rats by medullary infusion of a low dose of
L-NAME, a dose carefully determined to have no measurable
effect on basal MBF. In the absence of the ANG II-stimulated increase
of [NO], there was a reduction of both MBF and tissue PO2 of nearly 30%. These results demonstrated
the importance of the NO counterregulatory actions on the regulation of
MBF and oxygen delivery. Since Navar et al. (74) found
that, even under normal conditions, medullary tissue ANG II
concentrations are significantly higher than those of the renal cortex,
the regional generation of NO within the medulla could be of
substantial importance even in reducing the basal vasoconstrictor
actions of ANG II in this region of the kidney.
|
The effects of NE on medullary NO release have also been examined.
Several studies found that NE can induce NO release through the
2-receptors (35, 68, 135).
2-Activation appears to increase the influence of NO in
the glomeruli and proximal tubules of rats (130), and it
has been shown that the vasculature becomes more sensitive to
2-receptor stimulation with chronic NOS inhibition (31). As summarized in Fig. 6B, studies
have demonstrated the in vivo effects of NE on the medullary
circulation. In response to 1-h intravenous infusions of subpressor
amounts of NE (0.1 µg · kg
1 · min
1),
medullary [NO] increased 43% (135). This response was
inhibited with a selective
2-adrenergic inhibitor
(135). As was observed in the ANG II studies
(138), when medullary NOS activity was blunted by
medullary infusion of a low dose of L-NAME, the NE-induced rise of tissue [NO] was abolished and a reduction of both MBF and
tissue PO2 of nearly 30% was observed
(135). These results again demonstrated the importance of
the NO counterregulatory actions on the regulation of MBF and oxygen delivery.
Similar findings were also obtained in studies using subpressor amounts
of AVP (2 ng · kg
1 · min
1)
in which a 35% increase of medullary NO was observed
(89), a response mediated via the V2-type
receptor. These observations were consistent with the direct
observations that AVP stimulated NO production in the epithelial cells
of inner medullary collecting ducts (IMCD) as determined by fluorescent
microscopy (67) and other reports that AVP stimulated
increases of urinary cGMP concentrations (103) and that
the inhibition of NOS acutely enhanced systemic pressor responses to
AVP (35, 109).
Together, these studies demonstrated two important aspects of medullary NO production. First, subpressor elevations of circulating ANG II, NE, and AVP result in a substantial increase of renal medullary NO production. Second, one of the important functions of medullary NO production is related to the counterregulatory actions of this NO in response to stimulation by vasoconstrictor stimuli. The rise of medullary NO stimulated by these vasoconstrictor compounds significantly buffers both the reduction of MBF and tissue PO2.
| |
RENAL MEDULLARY NO PROTECTS AGAINST CHRONIC ANG II-, NE-, AND AVP-INDUCED HYPERTENSION |
|---|
|
|
|---|
On the basis of the acute observations described above, a series
of studies was carried out in chronically instrumented rats to
determine whether the stimulation of NO by vasoconstrictor compounds
would buffer or prevent chronic reductions of MBF and hypertension.
Studies determined whether selective blunting of NOS activity in the
renal medulla would result in a hypersensitivity to small elevations of
circulating vasoconstrictor compounds and consequently result in
hypertension. A dose of L-NAME (75 µg · kg
1 · h
1)
was used that did not reduce basal MBF >5% when administered into the
medullary interstitial space chronically for 2 wk (118). The same dose of L-NAME that significantly attenuated acute
increases of medullary [NO] produced by intravenous infusions of
subpressor amounts of ANG II, NE, and AVP (116-118).
Doses of ANG II (3.0 ng · kg
1 · min
1),
NE (0.1 µg · kg
1 · min
1),
and AVP (2.0 ng · kg
1 · min
1)
were determined that when administered intravenously did not result in
elevations of mean arterial pressure >5 mmHg when infused for 5-7
days to normal Sprague-Dawley rats (see Fig.
7). Each compound was then infused
intravenously, whereas the nonhypertensive dose of L-NAME
was infused chronically into the medullary interstitium to blunt
medullary NOS activity.
|
In the normal state (e.g., an absence of medullary L-NAME infusion), AVP infusion displayed a well-known response pattern with an initial rise of arterial pressure for the first several days of intravenous infusion and then returning to normal (19, 92). Chronic hypertension had never been observed previously with chronic elevations of plasma AVP in rats (19, 92), humans (48), or dogs (114). However, as seen in Fig. 7, in rats that received the subpressor chronic medullary infusion of L-NAME, AVP led to a sustained elevation of blood pressure (117). Similar studies were carried out to determine the responses to chronic intravenous infusions of subpressor doses of ANG II (116) and NE (118). Also shown in Fig. 7, hypertension occurred associated with sustained reductions of MBF (not shown) only when medullary NOS activity was blunted by the medullary interstitial infusion of L-NAME (116, 117).
The medullary circulation of rats therefore appears to be well protected from both the acute and chronic vasoconstrictor actions of small increases in circulating levels of ANG II, NE, and AVP. Although many of the details of these mechanisms remain to be elucidated, these studies show that NO-mediated responses play a key role in protecting the renal medulla from excessive vasoconstriction and chronic hypertension.
Other medullary systems may also be involved in protecting this region from underperfusion. On the basis of acute studies in anesthetized rats, one of the other medullary counterregulatory systems may be prostaglandin release. We have observed that rats pretreated with a cyclooxygenase inhibitor (meclofenemate) exhibited a significant reduction of medullary flow with subpressor intravenous infusion of ANG II (61). Similar responses have been observed with kinin receptor antagonists (24, 99). It has now also been found that the hemoxygenase enzymes are present at significantly greater concentrations in the renal medulla than in the cortex, and the production of medullary CO via the hemoxygenase pathway may participate in the control of flow to this region (134). It appears therefore that the renal medulla contains a number of redundant systems that could serve to protect blood flow to this region. However, only the NO system at this time has been sufficiently studied to conclude that it indeed represents a feedback control system for the long-term regulation of blood flow to the renal medulla.
The NO counterregulatory responses are of seemingly great importance in
maintaining an adequate blood flow to the outer medulla. The delivery
of oxygen to the mTAL is dependent on this blood flow. There is a high
rate of O2 utilization due to the high metabolic ion
transport activity of the thick ascending limbs of Henle that absorbs
nearly 25% of the filtered sodium load. Blood flow to the renal cortex
per gram of tissue is substantially higher in the cortex (700 ml · min
1 · 100 g
1) compared with the inner medulla (100 ml · min
1 · 100 g
1) (9); the hematocrit of vasa recta blood
is less than half (26%) of that of arterial blood (101).
The countercurrent flow in the vasa recta and shunting of
O2 between descending and ascending vasa recta account in
part for the falling gradient of PO2 observed from cortex to the tip of the papilla (6, 10, 12). These features result in the observed PO2 levels of
nearly 45 mmHg in the outer medulla falling progressively to <10 mmHg
in the inner medulla and tip of papilla (10, 11, 138).
This contributes to the cells in the deepest zone of the outer medulla
receiving less oxygen, making them more susceptible to ischemic
injury than cells situated in the cortex (12). The
vulnerability of the medulla to underperfusion is expressed by
tubulointerstitial injuries in the juxtamedullary region seen early in
the development of hypertension in rats (22, 26, 38, 94,
131) and humans (7).
| |
GENETIC RAT MODEL OF REDUCED MEDULLARY NO PRODUCTION: THE DAHL SS RAT |
|---|
|
|
|---|
It has been found that salt-sensitive Dahl rats (SS) exhibit a
reduced capacity to generate NO within the renal medulla. The outer
medulla NOS enzyme activity was found to be nearly one-third less in SS
rats than in normotensive salt-resistant BN rats, although NOS activity
was nearly the same in the inner medulla (119; Fig. 8B). Consistent with these
findings, the mRNA and protein for each of the three NOS isoforms was
also less in the outer medulla of SS rats compared with BN control rats
(Fig. 8, A and C; 119, 132). Most importantly,
although basal medullary [NO] was not significantly lower in SS
compared with BN rats, the ability of ANG II to stimulate an increase
of medullary NO was greatly blunted in SS rats as shown in Fig.
8D (119). These observations predict that the
renal medullary circulation of the SS inbred rat would be
hypersensitive to small elevations of circulating vasoconstrictor agents due to blunting of the NO counterregulatory system.
|
Studies were carried out to determine if SS rats resembled
Sprague-Dawley rats, in which medullary NOS activity was blunted by
selective delivery of L-NAME chronically into the medullary interstitium. As summarized in Fig. 9A,
chronic intravenous infusion of ANG
II (3.0 ng · kg
1 · min
1)
failed to induce a rise of mean arterial pressure in the
salt-insensitive BN rats as had been found earlier in Sprague-Dawley
rats (119). However, this same dose of systemically
delivered ANG II resulted in sustained hypertension in SS rats. It is
important to recognize that both the SS and BN rats were maintained on
a low (0.4%) salt intake throughout the study. These results were
consistent with the acute responses of MBF to low-dose acute
intravenous ANG II infusions (5.0 ng · kg
1 · min
1).
That is, ANG II significantly reduced MBF in SS rats, but not in BN
rats (119). The ability of the BN rats to buffer ANG
II-induced reductions of MBF but not in SS rats was also consistent
with observations that ANG II induced a significant increase of
medullary interstitial [NO] of BN rats, but failed to do so in SS
rats (119).
|
Similar studies were carried out with chronic intravenous infusion of
AVP (132). As shown in Fig. 9B, mean arterial
pressure in SS rats maintained on a low (0.4%)-salt diet increased
from a control of 127 mmHg to an average of 147 mmHg after 14 days of
AVP infusion (2.0 ng · kg
1 · min
1).
These were remarkable observations, because it was the first time that
AVP produced sustained hypertension without pharmacological manipulations or surgical reductions of renal mass (54).
Northern blot analysis of renal outer medullary tissue in this study
demonstrated that SS rats maintained on a low (0.4%)-salt diet
expressed NOS I and NOS II mRNA levels that were significantly less
than that found in BN rats maintained on the same low salt intake (132; Fig. 8A).
Taken together, the results of studies in both Sprague-Dawley rats receiving a medullary infusion of a low dose of L-NAME and in SS rats indicate that an impaired NO counterregulatory system in the renal medulla results in reduction of blood flow to this region and an increased susceptibility to develop hypertension in face of small elevations of circulating vasoconstrictor compounds such as ANG II, AVP, and NE.
| |
EVIDENCE THAT L-ARG UPTAKE IN THE RENAL MEDULLA PARTICIPATES IN THE REGULATION OF NO PRODUCTION |
|---|
|
|
|---|
Both oral and intravenous administration of the NOS substrate
L-Arg in large amounts have been shown to be capable of
preventing salt-induced hypertension in SS rats (15, 32, 90,
91). It has also been found in anesthetized rats that
pressure-natriuresis and transmission of perfusion pressure into the
renal interstitium were normalized by long-term L-Arg
treatment (90, 91). These observations led us to
hypothesize that the major antihypertensive actions of
L-Arg in SS rats could be mediated largely through actions
of this NO precursor, specifically within the renal medulla. A
threshold dose of L-Arg was found that when infused into
the medullary interstitium increased renal MBF without altering CBF in
anesthetized SS rats. This dose (300 µg · kg
1 · min
1)
was then infused chronically into the renal medullary interstitium of
SS rats to determine the effects of this regional L-Arg
administration on salt-induced hypertension in these rats (65,
66). Remarkably, as daily salt diet was increased from 0.4% to
4.0%, mean arterial pressure remained nearly unchanged over 1 wk in SS
rats receiving the medullary infusion of L-Arg (Fig.
10). In contrast, in SS rats receiving
the saline vehicle control infusion, mean arterial pressure increased
from a control level of 120 to 165 mmHg over the same time period. The
same dose of medullary infused L-Arg that prevented salt-induced hypertension in SS rats failed to blunt the development of
hypertension when administered intravenously to SS rats. It was found
that SS rats receiving the high-salt diet exhibited a significant
reduction of MBF (65). This reduction of flow to the renal
medulla of the SS rat was prevented by chronic medullary interstitial
delivery of L-Arg with no rise of arterial pressure observed. These data, as summarized in Fig. 10, indicated that the
prevention of salt-sensitivity in SS rats was due specifically to the
action of L-Arg on the renal medullary function and that SS
rats may have a deficit of medullary substrate availability that could
account in part for the observed reduction in NO production in this
region of the kidney.
|
Studies carried out to characterize the pathway of cellular uptake of L-Arg determined the influence of cellular L-Arg uptake on NOS enzymatic activity in IMCD cells from Sprague-Dawley rat kidneys (129). It was found that L-Arg uptake was predominantly mediated by a high-affinity y+ transporter system, a sodium-independent, trans-stimulated cationic transporter encoded by the CAT 1 gene. The y+ transporter system consists of a family of four genes, designated as CAT1, CAT2A, CAT2B, and CAT3, but the only transporter found in IMCD was CAT1. Biochemical transport studies using L-[3H]arginine found that the L-Arg transport system was saturable and inhibited by the cationic amino acids L-lysine, L-homoarginine, and L-ornithine, but was unaffected by the neutral amino acids L-leucine, L-serine, and L-glutamine. Both L-ornithine and L-lysine inhibited NOS enzymatic activity in a dose-dependent manner in IMCD cells, supporting the important role of L-Arg transport for NO production by this tubular segment in the renal medulla.
To determine whether chronic inhibition of L-Arg uptake in the renal medulla would reduce [NO] and produce hypertension, the effects of renal medullary infusion of cationic amino acids and an antisense oligonucleotide for CAT1 were determined in Sprague-Dawley rats (41). These studies demonstrated that chronic inhibition of L-Arg uptake in the renal medulla with a CAT1 antisense oligonucleotide or by coadministration of other competing cationic amino acids led to a sustained reduction of NO and the development of hypertension (41). In contrast, chronic intravenous infusion of the same dose of these cationic amino acids did not change NO in the medulla nor alter arterial pressure. These studies provide evidence that the in vivo production of NO and the regulation of MBF of the rat kidney are partially dependent on the cellular uptake of L-Arg by a y+ transport system. It remains to be determined if this system is altered in the Dahl salt-sensitive model of hypertension.
Perspectives
The overall consequences of chronic renal medullary underperfusion are beginning to be understood, and there is now considerable evidence that chronic reductions of MBF alone are sufficient to produce hypertension (16-18, 50, 64, 76, 92). The vulnerability of the medulla appears to be expressed by tubulointerstitial injuries in the juxtamedullary region seen early in the development of hypertension in rats (22, 26, 38, 94, 131) and humans (7). The current review has summarized evidence supporting the view that NO production within the renal medulla plays a special role in the regulation of blood flow to this region. The disproportionately higher production of NO in the renal medulla compared with the cortex acts in two significant ways to influence the regulation of fluid and electrolyte homeostasis. First, NO can directly reduce tubular reabsorption of sodium in the mTAL of Henle. Second, NO plays an important role in maintaining the metabolic needs of the medullary nephron function and the concentration gradients for urine concentrating mechanisms through the regulation of MBF. Although the relative importance of the direct tubular effects of NO compared with the secondary consequences of altered MBF remains to be clearly defined, it is evident that the medullary actions of NO play a key role in fluid and electrolyte homeostasis and in the long-term regulation of arterial pressure. When the production of NO within the renal medulla is compromised, either pharmacologically or as a result of genetic or pathological states, both the vasoconstrictor and tubular transport effects of elevated levels of circulating vasoconstrictor hormones are exaggerated due the reduced counterregulatory actions of NO. It is also now evident that the mechanisms whereby NO controls these various functions are more complicated than appreciated previously. This has been shown by the paracrine nature of the system and the cross-talk between NO production in epithelial mTAL and the pericytes of the vasa recta in the outer medulla serving to match blood flow with tubular metabolic transport activity. It is also now evident that L-Arg participates in the regulation of NO production in the renal medulla, and this must be considered in states of altered NO production. We and others have begun to explore the interesting interactions between the production of oxygen free radicals, cytochrome P-450 metabolites, and NO production within the kidney. These studies are beginning to reveal other important pathways whereby medullary NO participates in the regulation of renal medullary function and will be topics of future reviews.| |
ACKNOWLEDGEMENTS |
|---|
The authors thank Dr. M. Liang and M. Skelton for critical review of this manuscript.
The work presented in this review was supported by National Heart, Lung, and Blood Institute Grants HL-29587, HL-49219, HL-54998. D. Mattson was an American Heart Association Established Investigator (Grant 0040190N).
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: A. W. Cowley, Jr., Dept. of Physiology, Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI 53226 (E-mail: cowley{at}mcw.edu).
10.1152/ajpregu.00701.2002
| |
REFERENCES |
|---|
|
|
|---|
1.
Alberola, AM,
Salazar FJ,
Nakamura T,
and
Granger JP.
Interacting between angiotensin II and nitric oxide in control of renal hemodynamics in conscious dogs.
Am J Physiol Regul Integr Comp Physiol
267:
R1472-R1478,
1994
2.
Bachman, S,
and
Mundel P.
Nitric oxide in the kidney: synthesis, localization, and function.
Am J Kidney Dis
24:
112-129,
1994[Web of Science][Medline].
3.
Bankir, L,
and
de Rouffignac C.
Urinary concentrating ability: insights from comparative anatomy.
Am J Physiol Regul Integr Comp Physiol
249:
R463-R666,
1985.
4.
Bankir, L,
Kaissling B,
de Rouffignac C,
and
Kriz W.
The vascular organization of the kidney of Psammomys obesus.
Anat Embryol (Berl)
155:
149-160,
1979[Medline].
5.
Baylis, C,
and
Qiu C.
Importance of nitric oxide in the control of renal hemodynamics.
Kidney Int
49:
1727-1731,
1996[Web of Science][Medline].
6.
Biondi, ML,
Dousa T,
Vanhoutte P,
and
Romero JC.
Evidences for the existence of endothelium-derived relaxing factor in the renal medulla.
Am J Hypertens
3:
876-878,
1990[Web of Science][Medline].
7.
Bohle, A,
and
Ratschek M.
The compensated and the decompensated form of benign nephrosclerosis.
Pathol Res Pract
174:
357-367,
1982[Web of Science][Medline].
8.
Boulanger, CM,
Caputo L,
and
Levy BI.
Endothelial AT1-mediated release of nitric oxide decreases angiotensin II contractions in rat carotid artery.
Hypertension
26:
752-757,
1995
9.
Brenner, BM,
Zatz R,
and
Ichikawa I.
The renal circulation.
In: The Kidney, edited by Brenner BM,
and Rector FC.. Philadelphia, PA: Saunders, 1986, p. 93-126.
10.
Brezis, M,
Heyman SN,
Dinour D,
Epstein FH,
and
Rosen S.
Role of nitric oxide in renal medullary oxygenation. Studies in isolated and intact rat kidneys.
J Clin Invest
88:
390-395,
1991[Web of Science][Medline].
11.
Brezis, M,
Heyman SN,
and
Epstein FH.
Determinants of intrarenal oxygenation II. Hemodynamic effects.
Am J Physiol Renal Fluid Electrolyte Physiol
267:
F1063-F1068,
1994
12.
Brezis, M,
and
Rosen S.
Hypoxia of the renal medulla
its implications for disease.
N Engl J Med
332:
647-655,
1995
13.
Cattel, V,
and
Cook HT.
Glomerular NO synthase activity in mesangial cell immune injury.
Exp Nephrol
1:
36-40,
1993[Web of Science][Medline].
14.
Chaki, S,
and
Inagami T.
New signaling mechanism of angiotensin II in neuroblastoma neuro-2A cells: activation of soluble guanylyl cylase via nitric oxide synthesis.
Mol Pharmacol
43:
603-608,
1993[Abstract].
15.
Chen, PY,
and
Sanders PN.
Role of nitric oxide synthesis in salt-sensitive hypertension in Dahl/Rapp rats.
Hypertension
22:
812-818,
1993
16.
Cowley, AW, Jr.
Role of the renal medulla in volume and arterial pressure regulation.
Am J Physiol Regul Integr Comp Physiol
273:
R1-R15,
1997
17.
Cowley, AW, Jr,
Mattson DL,
Lu S,
and
Roman RJ.
The renal medulla and hypertension.
Hypertension
25:
663-673,
1995
18.
Cowley, AW, Jr,
and
Roman RJ.
The role of the kidney in hypertension.
JAMA
275:
1581-1589,
1996
19.
Cowley, AW, Jr,
Szczepanska-Sadowska E,
Stepniakowski K,
and
Mattson DL.
Chronic intravenous administration of V1 arginine vasopressin agonist results in sustained hypertension.
Am J Physiol Heart Circ Physiol
267:
H751-H756,
1994
20.
Deng, X,
Welch WJ,
and
Wilcox CS.
Role of nitric oxide in short-term and prolonged effects of angiotensin II on renal hemodynamics.
Hypertension
27:
1173-1179,
1996
21.
Dickhout, JG,
Mori T,
and
Cowley AW, Jr.
Tubulovascular nitric oxide crosstalk: buffering of angiotensin II-induced vasoconstriction.
Circ Res
91:
487-493,
2002
22.
Eng, E,
Veniant M,
Floege J,
Fingerle J,
Alpers CE,
Menard J,
Clozel JP,
and
Johnson RJ.
Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension.
Am J Hypertens
7:
177-185,
1994[Web of Science][Medline].
23.
Fenoy, FJ,
Ferrar P,
Carbonell L,
and
Garcia-Salom M.
Role of nitric oxide on papillary blood flow and pressure natriuresis.
Hypertension
25:
408-414,
1995
24.
Fenoy, FJ,
Scicli G,
Carretero O,
and
Roman RJ.
Effect of angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to Captopril.
Hypertension
17:
1038-1044,
1991
25.
Forstermann, U,
Pollock JS,
and
Nakane M.
Nitric oxide synthases in the cardiovascular system.
Trends Cardiovasc Med
3:
104-110,
1993.
26.
Frohlich, ED,
and
Arthur C.
Corcoran Lecture: influence of nitric oxide and angiotensin II on renal involvement in hypertension.
Hypertension
29:
188-193,
1997
27.
Gross, V,
Kurth TM,
Skelton MM,
Mattson DL,
and
Cowley AW, Jr.
Effects of daily sodium intake and ANG II on cortical and medullary renal blood flow in conscious rats.
Am J Physiol Regul Integr Comp Physiol
274:
R1317-R1323,
1998
28.
Guarasci, G,
and
Kline RL.
Pressure-natriuresis following acute and chronic inhibition of nitric oxide synthase in rats.
Am J Physiol Regul Integr Comp Physiol
270:
R469-R478,
1996
29.
Hayokawa, H,
and
Ray L.
Nitric oxide activity and renal injury in genetic hypertension.
Hypertension
31:
266-270,
1998
30.
He, XR,
Greenberg S,
Briggs JP,
and
Schnerman JB.
Effect of nitric oxide on renin secretion II. Studies in the perfused juxtaglomerular apparatus.
Am J Physiol Renal Fluid Electrolyte Physiol
268:
F953-F959,
1995
31.
Hennington, BS,
Zhang H,
Miller MJ,
Granger JP,
and
Reckelhoff JF.
Angiotensin II stimulates synthesis of endothelial nitric oxide synthase.
Hypertension
31:
283-288,
1988.
32.
Hu, L,
and
Manning RD.
Role of nitric oxide in regulation of long-term pressure-natriuresis relationship in Dahl rats.
Am J Physiol Heart Circ Physiol
268:
H2375-H2383,
1995
33.
Huang, PL,
Huang Z,
Mashimo H,
Block KD,
Moskowitz MA,
Bevan JA,
and
Fishman MC.
Hypertension in mice lacking the gene for endothelial nitric oxide synthase.
Nature
377:
239-242,
1995[Medline].
34.
Ikeda, U,
Maeda Y,
Kawahara Y,
Yokoyama M,
and
Shimada K.
Angiotensin II augments cytokine-stimulated nitric oxide synthesis in rat cardiac myocytes.
Circulation
92:
2683-2689,
1995
35.
Ikenaga, H,
Fallet RW,
and
Carmines PK.
Basal nitric oxide production curtails arteriolar vasoconstrictor responses to ANG II in rat kidney.
Am J Physiol Renal Fluid Electrolyte Physiol
271:
F365-F373,
1996
36.
Ishii, K,
Chang B,
Kerwin JF, Jr,
Wagenaar FL,
Huang ZS,
and
Murad F.
Formation of endothelium-derived relaxing factor in porcine kidney epithelial LLC-PK1 cells: an intra- and intercellular messenger for activation of soluble guanylate cyclase.
J Pharmacol Exp Ther
256:
38-43,
1991
37.
Ito, S,
Johnson CS,
and
Carretero OA.
Modulation of angiotensin II-induced vasoconstriction by endothelium-derived relaxing factor in the isolated microperfused rabbit afferent arteriole.
J Clin Invest
87:
1656-1663,
1991[Web of Science][Medline].
38.
Johnson, RJ,
Alpers CE,
Yoshimura A,
Lombardi D,
Pritzel P,
Floege J,
and
Schwartz SM.
Renal injury from angiotensin II-mediated hypertension.
Hypertension
19:
464-474,
1992
39.
Kaissling, B,
and
Kriz W.
Structural analysis of the rabbit kidney.
Adv Anat Embryol Cell Biol
56:
1-123,
1979[Medline].
40.
Kaissling, B,
de Rouffignac C,
Barrett JM,
and
Kriz W.
The structural organization of the kidney of the desert rodent Psammomys obesus.
Anat Embryol (Berl)
148:
121-143,
1975[Medline].
41.
Kakoki, M,
Wang W,
and
Mattson DL.
Cationic amino acid transport in the renal medulla and blood pressure regulation.
Hypertension
39:
287-292,
2002
42.
Kakoki, M,
Zou AP,
and
Mattson DL.
The influence of nitric oxide synthase 1 on blood flow and interstitial nitric oxide in the kidney.
Am J Physiol Regul Integr Comp Physiol
281:
R91-R97,
2001
43.
Kone, BC,
and
Baylis C.
Biosynthesis and homeostatic roles of nitric oxide in the normal kidney.
Am J Physiol Renal Physiol
272:
F561-F578,
1997
44.
Kriz, W.
Structural organization of the renal medulla: comparative and functional aspects.
Am J Physiol Regul Integr Comp Physiol
241:
R3-R16,
1981
45.
Lamas, S,
Marsden PA,
Li GK,
Tempst P,
and
Michel T.
Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform.
Proc Natl Acad Sci USA
89:
6348-6352,
1992
46.
Lancaster, JR, Jr.
The physical properties of nitric oxide: determinants of the dynamics of NO in tissue.
In: Nitric oxide
Biology and Pathobiology, edited by Ignanno LJ.. New York: Academic, 2000.
47.
Lancaster, JR, Jr.
A tutorial on the diffusibility and reactivity of free nitric oxide.
Nitric Oxide
1:
18-30,
1997[Web of Science][Medline].
48.
Leaf, A,
Bartter FC,
Santos RF,
and
Wrong O.
Evidence in man that urinary electrolyte loss induced by pitressin is a function of water retention.
J Clin Invest
32:
868-878,
1953[Web of Science][Medline].
49.
Lemley, KV,
and
Kriz W.
Anatomy of the renal interstitium.
Kidney Int
39:
370-381,
1991[Web of Science][Medline].
50.
Liang, M,
and
Knox FG.
Production and functional roles of nitric oxide in the proximal tubule.
Am J Physiol Regul Integr Comp Physiol
278:
R1117-R1124,
2000
51.
Lu, S,
Mattson DL,
Roman RJ,
Becker CG,
and
Cowley AW, Jr.
Assessment of changes in intrarenal blood flow in conscious rats using laser Doppler flowmetry.
Am J Physiol Renal Fluid Electrolyte Physiol
264:
F956-F962,
1993
52.
Lu, SH,
Mattson DL,
and
Cowley AW, Jr.
Renal medullary captopril delivery lowers blood pressure in spontaneously hypertensive rats.
Hypertension
23:
337-345,
1994
53.
Majid, DSA,
and
Navar LG.
Suppression of blood flow autoregulation plateau during nitric oxide blockade in canine kidney.
Am J Physiol Renal Fluid Electrolyte Physiol
262:
F40-F46,
1992
54.
Manning, RD, Jr,
Guyton AC,
Coleman TG,
and
McCaa RE.
Hypertension in dogs during antidiuretic hormone and hypotonic saline infusion.
Am J Physiol Heart Circ Physiol
236:
H314-H322,
1979
55.
Manning, RD, Jr,
Hu L,
Tan DY,
and
Meng S.
Role of abnormal nitric oxide system in salt-sensitive hypertension.
Am J Hypertens
14:
68S-73S,
2001[Web of Science][Medline].
56.
Mattson, DL,
and
Bellehumeur TG.
Neural nitric oxide synthase in the renal medulla and blood pressure regulation.
Hypertension
28:
297-303,
1996
57.
Mattson, DL,
and
Cowley AW, Jr.
Kinin actions on renal papillary blood flow and sodium excretion.
Hypertension
6:
961-965,
1993.
58.
Mattson, DL,
and
Higgins DJ.
Influence of dietary sodium intake on renal medullary nitric oxide synthase.
Hypertension
27:
688-692,
1996
59.
Mattson, DL,
Lu S,
Nakanishi K,
Papanek PE,
and
Cowley AW, Jr.
Effect of chronic renal medullary nitric oxide inhibition on blood pressure.
Am J Physiol Heart Circ Physiol
266:
H1918-H1926,
1994
60.
Mattson, DL,
Maeda CY,
Bachman TD,
and
Cowley AW, Jr.
Inducible nitric oxide synthase and blood pressure.
Hypertension
31:
15-20,
1998
61.
Mattson, DL,
and
Roman RJ.
Role of kinins and AII in the renal hemodynamic response to captopril.
Am J Physiol Renal Fluid Electrolyte Physiol
260:
F670-F679,
1991
62.
Mattson, DL,
Roman RJ,
and
Cowley AW, Jr.
Role of nitric oxide in renal papillary blood flow and sodium excretion.
Hypertension
19:
766-769,
1992
63.
Mattson, DL,
and
Wu F.
Nitric oxide synthase activity and isoforms in rat renal vasculature.
Hypertension
35:
337-341,
2000
64.
Michel, CC.
Renal medullary microcirculation: architecture and exchange.
Microcirculation
2:
125-139,
1995[Medline].
65.
Miyata, N,
and
Cowley AW, Jr.
Renal intramedullary infusion of L-arginine prevents reduction of medullary blood flow and hypertension in Dahl salt-sensitive rats.
Hypertension
33:
446-450,
1999
66.
Miyata, N,
Zou AP,
Mattson DL,
and
Cowley AW, Jr.
Renal medullary interstitial infusion of L-arginine prevents hypertension in Dahl salt-sensitive rats.
Am J Physiol Regul Integr Comp Physiol
275:
R1667-R1673,
1998
67.
Mori, T,
Dickhout JG,
and
Cowley AW, Jr.
Vasopressin increases intracellular nitric oxide concentration via Ca2+ signaling in inner medullary collecting duct.
Hypertension
39:
465-469,
2002
68.
Moridani, BA,
and
Kline RL.
Effect of endogenous L-arginine on the measurement of nitric oxide synthase activity in the rat kidney.
Can J Physiol Pharmacol
74:
1210-1214,
1996[Web of Science][Medline].
69.
Moritoki, H,
Takeuchi S,
Hisayama T,
and
Kondoh W.
Nitric oxide synthase responsible for L-arginine-induced relaxation of rat aortic rings in vitro may be an inducible type.
Br J Pharmacol
107:
361-366,
1992[Web of Science][Medline].
70.
Nakanishi, K,
Hara N,
and
Nagai Y.
Salt-sensitive hypertension in conscious rats induced by chronic nitric oxide blockade.
Am J Hypertens
15:
150-156,
2002[Web of Science][Medline].
71.
Nakanishi, K,
Mattson DL,
and
Cowley AW, Jr.
Role of renal medullary blood flow in the development of L-NAME hypertension in rats.
Am J Physiol Regul Integr Comp Physiol
268:
R317-R323,
1995
72.
Nakanishi, K,
Mattson DL,
Gross V,
Roman RJ,
and
Cowley AW, Jr.
Control of renal medullary flow by vasopressin V1 and V2 receptors.
Am J Physiol Regul Integr Comp Physiol
269:
R193-R200,
1995
73.
Navar, LG,
Harrison-Bernard LM,
Nishiyama A,
and
Kobori H.
Regulation of intrarenal angiotensin II in hypertension.
Hypertension
39:
316-322,
2002
74.
Navar, JG,
Imig JD,
Zou L,
and
Wang CT.
Intrarenal production of angiotensin II.
Semin Nephrol
17:
412-422,
1997[Web of Science][Medline].
75.
Navar, LG,
Inscho EW,
Majid DSA,
Imig JD,
Harrison-Bernard L,
and
Mitchell KD.
Paracrine regulation of the renal microcirculation.
Physiol Rev
76:
425-536,
1996
76.
Ni, Z,
and
Vaziri ND.
Effect of salt loading on nitric oxide synthase expression in normotensive rats.
Am J Hypertens
14:
155-163,
2000.
77.
Nishimoto, Y,
Tomida T,
Matsui H,
Ito T,
and
Okumura K.
Decrease in renal medullary endothelial nitric oxide synthase of fructose-fed, salt-sensitive hypertensive rats.
Hypertension
40:
109-194,
2002.
78.
Ortiz, PA,
and
Garvin JL.
Autocrine effects of nitric oxide on HCO
79.
Ortiz, PA,
and
Garvin JL.
NO inhibits NaCL absorption by rat thick ascending limb through activation of cGMP stimulated phosphodiesterase.
Hypertension
37:
467-471,
2000.
80.
Ortiz, P,
and
Garvin JL.
Role of nitric oxide in the regulation of nephron transport.
Am J Physiol Renal Physiol
282:
F777-F784,
2002
81.
Pallone, TL.
The extraglomerular circulation of the kidney.
In: The Kidney: Physiology and Pathophysiology (3rd ed.), edited by Seldin DW,
and Giebisch G.. Philadelphia, PA: Lippincott Williams and Wilkins, 2000, p. 791-822.
82.
Pallone, TL,
Robertson CR,
and
Jamison RL.
Renal medullary microcirculation.
Physiol Rev
70:
885-920,
1990
83.
Pallone, TL,
Silldorff EP,
and
Cheung JY.
Response of isolated rat descending vasa recta to bradykinin.
Am J Physiol Heart Circ Physiol
274:
H752-H759,
1998
84.
Pallone, TL,
Silldorff EP,
and
Turner MR.
Intrarenal blood flow: microvascular anatomy and the regulation of medullary perfusion.
Clin Exp Pharmacol Physiol
25:
383-392,
1998[Web of Science][Medline].
85.
Pallone, TL,
Silldorff EP,
and
Zhang Z.
Inhibition of calcium signaling in descending vasa recta endothilia by ANG II.
Am J Physiol Heart Circ Physiol
278:
H1248-H1255,
2000
86.
Pallone, TL,
Zhang Z,
and
Rhinehart K.
Physiology of the renal medullary microcirculation.
Am J Physiol Renal Physiol
284:
F253-F266,
2003
87.
Parekh, N,
Dobrowolski L,
Zou AP,
and
Steinhausen M.
Nitric oxide modulates angiotensin II and norepinephrine dependent vasoconstriction in rat kidney.
Am J Physiol Regul Integr Comp Physiol
270:
R1-R6,
1996
88.
Park, F,
Mattson DL,
Roberts LA,
and
Cowley AW, Jr.
Evidence for the presence of smooth muscle
-actin within penicytes of the renal medulla.
Am J Physiol Regul Integr Comp Physiol
273:
R1742-R1748,
1997
89.
Park, F,
Zou AP,
and
Cowley AW, Jr.
Arginine vasopressin-mediated stimulation of nitric oxide within the rat renal medulla.
Hypertension
32:
896-901,
1998
90.
Patel, AR,
Granger JP,
and
Kirchner KA.
L-Arginine improves transmission of perfusion pressure to the renal interstitial in Dahl salt-sensitive rats.
Am J Physiol Regul Integr Comp Physiol
266:
R1730-R1735,
1994
91.
Patel, AR,
Layne S,
Watts D,
and
Kirchner KA.
L-Arginine administration normalizes pressure natriuresis in hypertensive Dahl rats.
Hypertension
22:
863-869,
1993
92.
Pawloski, CM,
Eicker NM,
Ball LM,
Mangiapane ML,
and
Fink GD.
Effect of circulating vasopressin on arterial pressure regulation in rats.
Am J Physiol Heart Circ Physiol
257:
H209-H218,
1989
93.
Pfeilschifter, J,
Kunz D,
and
Mühl H.
Nitric oxide: an inflammatory mediator of glomerular mesangial cells.
Nephron
64:
518-525,
1993[Web of Science][Medline].
94.
Pichler, R,
Franceschini N,
Young B,
Hugo C,
Andoh TF,
Burdmann EA,
Shankland SJ,
Alpers CE,
Bennett WM,
and
Couser WG.
Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin.
J Am Soc Nephrol
6:
1186-1196,
1995[Abstract].
95.
Plato, CF,
Pollack DM,
and
Garvin JL.
Endothelin inhibits thick ascending limb chloride flux via ETB receptor-mediated NO release.
Am J Physiol Renal Physiol
279:
F326-F333,
2000
96.
Raij, L,
and
Baylis C.
Glomerular actions of nitric oxide.
Kidney Int
48:
20-32,
1995[Web of Science][Medline].
97.
Reinhardt, K,
Zhang Z,
and
Pallone TL.
Ca2+ signaling and membrane potential in descending vasa recta pericytes and endothelia.
Am J Physiol Renal Physiol
283:
F852-F860,
2002
98.
Roczniak, A,
Zimpelmann J,
and
Burns KD.
Effect of dietary salt on neuronal nitric oxide synthase in the inner medullary collecting duct.
Am J Physiol Renal Physiol
275:
F46-F54,
1998
99.
Roman, RJ.
Altered pressure-natriuresis relationship in young spontaneously hypertensive rats.
Hypertension
9:
III-130-III-136,
1987.
100.
Roman, RJ.
P450 metabolites of arachidonic acid in the control of cardiovascular function.
Physiol Rev
82:
131-185,
2002
101.
Roman, RJ,
Cowley AW, Jr,
Garcia-Estan J,
and
Lombard JH.
Pressure-diuresis in volume expanded rats: cortical and medullary hemodynamics.
Hypertension
12:
168-176,
1988
102.
Roman, RJ,
and
Zou AP.
Influence of the renal medullary circulation on the control of sodium excretion.
Am J Physiol Regul Integr Comp Physiol
265:
R963-R973,
1993
103.
Rudichenko, VM,
and
Beierwaltes WH.
Arginine vasopressin-induced renal vasodilation mediated by nitric oxide.
J Vasc Res
32:
100-105,
1995[Web of Science][Medline].
104.
Schnackenberg, C,
Patel AR,
Kirchner KA,
and
Granger JP.
Nitric oxide, the kidney and hypertension.
Clin Exp Pharmacol Physiol
24:
600-606,
1997[Web of Science][Medline].
105.
Schnackenberg, CG,
Wilkins FC,
and
Granger JP.
Role of nitric oxide in modulating the vasoconstrictor actions of angiotensin II in preglomerular and post glomerular vessels in dogs.
Hypertension
26:
1024-1029,
1995
106.
Scott-Burden, T,
Elizondo E,
Ge T,
Boulanger CM,
and
Vanhoutte PM.
Simultaneous activation of adenylyl cyclase and protein kinase C induces production of nitric oxide by vascular smooth muscle cells.
Mol Pharmacol
46:
274-282,
1994[Abstract].
107.
Seikaly, MG,
Arent BS,
and
Seney FD.
Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat.
J Clin Invest
86:
1352-1357,
1990[Web of Science][Medline].
108.
Shultz, PJ,
Mahmoud AT,
Marletta MA,
and
Raij L.
Synthesis and action of nitric oxide in rat glomerular mesangial cells.
Am J Physiol Renal Fluid Electrolyte Physiol
261:
F600-F606,
1991
109.
Sieber, CC,
and
Grosymann RJ.
Nitric oxide indicates hyporeactivity to vasopressin in mesenteric vessels of portal hypertensive rats.
Gastroenterology
103:
235-239,
1992[Web of Science][Medline].
110.
Siragy, HM,
and
Carey RM.
The subtypes (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats.
J Clin Invest
100:
264-269,
1997[Web of Science][Medline].
111.
Silldorff, EP,
and
Pallone TL.
Adenosine signaling in outer medullary descending vasa recta.
Am J Physiol Regul Integr Comp Physiol
280:
R854-R861,
2001
112.
Silldorff, EP,
Yang S,
and
Pallone TL.
Prostaglandin E2 abrogates endothelin-induced vasoconstriction of outer medullary descending vasa recta in the rat.
J Clin Invest
95:
2734-2740,
1995[Web of Science][Medline].
113.
Singh, I,
Grams M,
Wang WH,
Yang T,
Killen P,
Smart A,
Schermann J,
and
Briggs JP.
Coordinate regulation of renal expression of nitric oxide synthase, rennin, and angiotensinogen mRNA by dietary salt.
Am J Physiol Renal Fluid Electrolyte Physiol
270:
F1027-F1037,
1996
114.
Smith, MJ, Jr,
Cowley AW, Jr,
Guyton AC,
and
Manning RD, Jr.
Acute and chronic effects of vasopressin in blood pressure, electrolytes, and fluid volumes.
Am J Physiol Renal Fluid Electrolyte Physiol
237:
F232-F240,
1979
115.
Sonntag, MA,
Deussen J,
and
Schader J.
Role of nitric oxide in local blood flow control in the anesthetized dog.
Pflügers Arch
420:
194-199,
1992[Web of Science][Medline].
116.
Szentivanyi, MJR,
Maeda CY,
and
Cowley AW, Jr.
Local renal medullary L-NAME enhances the effect of long-term angiotensin II treatment.
Hypertension
33:
440-445,
1999
117.
Szentivanyi, M, Jr,
Park F,
Maeda CY,
and
Cowley AW, Jr.
Nitric oxide in the renal medulla protects from vasopressin-induced hypertension.
Hypertension
35:
740-745,
2000
118.
Szentivanyi, M, Jr,
Zou AP,
Maeda CY,
Mattson DL,
and
Cowley AW, Jr.
Increase in renal medullary nitric oxide synthase activity protects from norepinephrine-induced hypertension.
Hypertension
35:
418-423,
2000
119.
Szentivanyi, M, Jr,
Zou AP,
Mattson DL,
Soares P,
Moreno C,
Roman RJ,
and
Cowley AW, Jr.
Renal medullary nitric oxide deficit of Dahl S rats enhances hypertensive actions of angiotensin II.
Am J Physiol Regul Integr Comp Physiol
280:
R266-R272,
2001.
120.
Tan, DY,
Meng S,
Cason GW,
and
Manning RD, Jr.
Mechanisms of salt-sensitive hypertension: role of inducible nitric oxide synthase.
Am J Physiol Regul Integr Comp Physiol
279:
R2297-R2303,
2000
121.
Terada, Y,
Tomita K,
Nonoguchi H,
and
Mammo F.
Polymerase chain reaction localization of constitutive nitric oxide synthase and soluble guanylyl cyclase messenger RNA's in microdissected rat nephron segments.
J Clin Invest
90:
659-663,
1992[Web of Science][Medline].
122.
Thorup, C,
and
Persson AEG
Inhibition of locally produced nitric oxide resets tubuloglomerular feedback mechanism.
Am J Physiol Renal Fluid Electrolyte Physiol
267:
F606-F611,
1994
123.
Tolins, JP,
and
Shultz PJ.
Endogenous nitric oxide synthesis determines sensitivity to the pressor effect of salt.
Kidney Int
46:
230-236,
1994[Web of Science][Medline].
124.
Turner, MR,
and
Pallone TL.
Vasopressin constricts outer medullary descending vasa recta isolated from rat kidneys.
Am J Physiol Renal Physiol
272:
F147-F151,
1997
125.
Ugie, K,
Yuen J,
Hoganth L,
Danziger R,
and
Star RA.
Localization and regulation of endothelial NO synthase mRNA expression in rat kidney.
Am J Physiol Renal Fluid Electrolyte Physiol
267:
F296-F302,
1994
126.
Vallon, V,
Peterson OW,
Gabbai FB,
Blantz RC,
and
Thomson SC.
Interactive control of renal function by
2-adrenergic system and nitric oxide: role of angiotensin II.
J Cardiovasc Pharmacol
26:
916-922,
1995[Web of Science][Medline].
127.
Wang, X,
Thomas SR,
and
Wexler AS.
Outer medullary anatomy and the urine concentrating mechanism.
Am J Physiol Renal Physiol
274:
F413-F424,
1998
128.
Wilcox, CS,
Welch WJ,
Murad F,
Gross SS,
Taylor G,
Lewis R,
and
Schmidt HH.
Nitric oxide synthase in macula densa regulates glomerular capillary pressure.
Proc Natl Acad Sci USA
89:
11993-11997,
1992
129.
Wu, F,
Cholewa B,
and
Mattson DL.
Characterization of L-arginine transporters in rat renal inner medullary collecting duct.
Am J Physiol Regul Integr Comp Physiol
278:
R1506-R1512,
2000
130.
Wu, F,
Park F,
Cowley AW, Jr,
and
Mattson DL.
Quantification of nitric oxide synthase activity in microdissected segments of the rat kidney.
Am J Physiol Renal Physiol
276:
F874-F881,
1999
131.
Young, BA,
Burdmann EA,
Johnson RJ,
Alpers CE,
Giachelli CM,
Eng E,
Andoh T,
Bennett WM,
and
Couser WG.
Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity.
Kidney Int
48:
439-448,
1995[Web of Science][Medline].
132.
Yuan, B,
and
Cowley AW, Jr.
Evidence that reduced renal medullary nitric oxide synthase activity of Dahl S rats enables small elevations of arginine vasopressin to produce sustained hypertension.
Hypertension
37:
524-528,
2001
133.
Zarahn, ED,
Ye X,
Ader AM,
Reagan LP,
and
Fluharty SJ.
Angiotensin-induced cyclic GMP production is mediated by multiple receptor subtypes and nitric oxide in NIE-115 neuroblastoma cells.
J Neurochem
58:
1960-1963,
1992[Web of Science][Medline].
134.
Zou, AP,
Billington H,
Su N,
and
Cowley AW, Jr.
Expression and actions of heme oxygenase in the renal medulla of rats.
Hypertension
35:
342-347,
2000
135.
Zou, AP,
and
Cowley AW, Jr.
2Adrenergic receptor-mediated increase in NO production buffers renal medullary vasoconstriction.
Am J Physiol Regul Integr Comp Physiol
279:
R769-R777,
2000
136.
Zou, AP,
and
Cowley AW, Jr.
Nitric oxide in renal cortex and medulla: an in vivo microdialysis study.
Hypertension
29:
194-198,
1997
137.
Zou, AP,
and
Cowley AW, Jr.
Role of nitric oxide in the control of renal function and salt sensitivity.
Curr Hypertens Rep
1:
178-186,
1999[Medline].
138.
Zou, AP,
Wu F,
and
Cowley AW, Jr.
Protective effect of angiotensin II induced increase in nitric oxide in the renal medullary circulation.
Hypertension
31:
271-276,
1997[Web of Science].
This article has been cited by other articles:
![]() |
M. Sendeski, A. Patzak, T. L. Pallone, C. Cao, A. E. Persson, and P. B. Persson Iodixanol, Constriction of Medullary Descending Vasa Recta, and Risk for Contrast Medium-induced Nephropathy Radiology, June 1, 2009; 251(3): 697 - 704. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Legrand, E. Almac, E. G. Mik, T. Johannes, A. Kandil, R. Bezemer, D. Payen, and C. Ince L-NIL prevents renal microvascular hypoxia and increase of renal oxygen consumption after ischemia-reperfusion in rats Am J Physiol Renal Physiol, May 1, 2009; 296(5): F1109 - F1117. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Nakano and D. M. Pollock Contribution of Endothelin A Receptors in Endothelin 1-Dependent Natriuresis in Female Rats Hypertension, February 1, 2009; 53(2): 324 - 330. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Cao, K. Payne, W. Lee-Kwon, Z. Zhang, S. W. Lim, J. Hamlyn, M. P. Blaustein, H. M. Kwon, and T. L. Pallone Chronic ouabain treatment induces vasa recta endothelial dysfunction in the rat Am J Physiol Renal Physiol, January 1, 2009; 296(1): F98 - F106. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu, R. J. Singh, K. Usa, B. C. Netzel, and M. Liang Renal medullary 11{beta}-hydroxysteroid dehydrogenase type 1 in Dahl salt-sensitive hypertension Physiol Genomics, December 12, 2008; 36(1): 52 - 58. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Wilcox and A. Pearlman Chemistry and Antihypertensive Effects of Tempol and Other Nitroxides Pharmacol. Rev., December 1, 2008; 60(4): 418 - 469. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Evans, B. S. Gardiner, D. W. Smith, and P. M. O'Connor Intrarenal oxygenation: unique challenges and the biophysical basis of homeostasis Am J Physiol Renal Physiol, November 1, 2008; 295(5): F1259 - F1270. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Sims, N. J. Rehrer, M. L. Bell, and J. D. Cotter Endogenous and exogenous female sex hormones and renal electrolyte handling: effects of an acute sodium load on plasma volume at rest J Appl Physiol, July 1, 2008; 105(1): 121 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Kempson, J. M. Edwards, A. Osborn, and M. Sturek Acute inhibition of the betaine transporter by ATP and adenosine in renal MDCK cells Am J Physiol Renal Physiol, July 1, 2008; 295(1): F108 - F117. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Li, L. Chen, F. Yi, M. Xia, and P.-L. Li Salt-Sensitive Hypertension Induced by Decoy of Transcription Factor Hypoxia-Inducible Factor-1{alpha} in the Renal Medulla Circ. Res., May 9, 2008; 102(9): 1101 - 1108. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Nakano, J. S. Pollock, and D. M. Pollock Renal medullary ETB receptors produce diuresis and natriuresis via NOS1 Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1205 - F1211. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Shi, D. Patschan, T. Epstein, M. S. Goligorsky, and J. Winaver Delayed recovery of renal regional blood flow in diabetic mice subjected to acute ischemic kidney injury Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1512 - F1517. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Guzik, N. E. Hoch, K. A. Brown, L. A. McCann, A. Rahman, S. Dikalov, J. Goronzy, C. Weyand, and D. G. Harrison Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction J. Exp. Med., October 1, 2007; 204(10): 2449 - 2460. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zhang and A. Edwards A model of nitric oxide tubulovascular cross talk in a renal outer medullary cross section Am J Physiol Renal Physiol, February 1, 2007; 292(2): F711 - F722. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Zhang, C. Cao, M. Mangano, Z. Zhang, E. P. Silldorff, W. Lee-Kwon, K. Payne, and T. L. Pallone Descending vasa recta endothelium is an electrical syncytium Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2006; 291(6): R1688 - R1699. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. W. Rajapakse, G. A. Eppel, R. E. Widdop, and R. G. Evans ANG II type 2 receptors and neural control of intrarenal blood flow Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2006; 291(6): R1669 - R1676. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yazdanpanah, F. A. Sayed-Tabatabaei, A. Hofman, Y. S. Aulchenko, B. A. Oostra, B. H.C. Stricker, H. A.P. Pols, S. W.J. Lamberts, J. C.M. Witteman, J. A.M.J.L. Janssen, et al. The {alpha}-Adducin Gene Is Associated With Macrovascular Complications and Mortality in Patients With Type 2 Diabetes. Diabetes, October 1, 2006; 55(10): 2922 - 2927. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Pittner, K. Rhinehart, and T. L. Pallone Ouabain modulation of endothelial calcium signaling in descending vasa recta Am J Physiol Renal Physiol, October 1, 2006; 291(4): F761 - F769. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Neuhofer and F.-X. Beck Survival in Hostile Environments: Strategies of Renal Medullary Cells Physiology, June 1, 2006; 21(3): 171 - 180. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Haller, J.-K. Park, C. Lindschau, M. Meyer, and J. Menne Intrarenal renin-angiotensin system -- important player of the local milieu Journal of Renin-Angiotensin-Aldosterone System, June 1, 2006; 7(2): 122 - 125. [PDF] |
||||
![]() |
R. A. Khalil Dietary salt and hypertension: new molecular targets add more spice Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R509 - R513. [Full Text] [PDF] |
||||
![]() |
M. G. Salom, B. Arregui, L. F. Carbonell, F. Ruiz, J. L. Gonzalez-Mora, and F. J. Fenoy Renal ischemia induces an increase in nitric oxide levels from tissue stores Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2005; 289(5): R1459 - R1466. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Persson Fluid volume or arterial pressure, that is the question J. Physiol., September 1, 2005; 567(2): 361 - 361. [Full Text] [PDF] |
||||
![]() |
G. Bianchi, P. Ferrari, and J. A. Staessen Adducin Polymorphism: Detection and Impact on Hypertension and Related Disorders Hypertension, March 1, 2005; 45(3): 331 - 340. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Wilcox and D. Gutterman Focus on oxidative stress in the cardiovascular and renal systems Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H3 - H6. [Full Text] [PDF] |
||||
![]() |
Z. Zhang, K. Rhinehart, G. Solis, J. Pittner, W. Lee-Kwon, W. J. Welch, C. S. Wilcox, and T. L. Pallone Chronic ANG II infusion increases NO generation by rat descending vasa recta Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H29 - H36. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Lee, J. M. Sasser, J. L. Hobbs, A. Boriskie, D. M. Pollock, P. K. Carmines, and J. S. Pollock Posttranslational regulation of NO synthase activity in the renal medulla of diabetic rats Am J Physiol Renal Physiol, January 1, 2005; 288(1): F82 - F90. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Pallone, C. Cao, and Z. Zhang Inhibition of K+ conductance in descending vasa recta pericytes by ANG II Am J Physiol Renal Physiol, December 1, 2004; 287(6): F1213 - F1222. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zeng, H. Sanada, H. Watanabe, G. M. Eisner, R. A. Felder, and P. A. Jose Functional genomics of the dopaminergic system in hypertension Physiol Genomics, November 17, 2004; 19(3): 233 - 246. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhang and T. L. Pallone Response of descending vasa recta to luminal pressure Am J Physiol Renal Physiol, September 1, 2004; 287(3): F535 - F542. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhang, K. Rhinehart, W. Kwon, E. Weinman, and T. L. Pallone ANG II signaling in vasa recta pericytes by PKC and reactive oxygen species Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H773 - H781. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. W. Rajapakse, R. J. Roman, J. R. Falck, J. J. Oliver, and R. G. Evans Modulation of V1-receptor-mediated renal vasoconstriction by epoxyeicosatrienoic acids Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2004; 287(1): R181 - R187. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |